Longevity Health Holdings Reports 4,000% Revenue Growth and Strategic Acquisitions in Latest 10-Q

Longevity Health Holdings, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company achieved net sales of $503,612 for the three months ended June 30, 2025, a substantial increase from $12,320 in the same period last year, marking a growth of over 4,000%. For the first half of 2025, net sales reached $1,013,965, compared to just $12,320 in the prior year. The gross profit for the second quarter was $302,658, up from $12,028 in the previous year, while the gross profit for the first half of 2025 was $572,481, compared to $12,028 in the same period of 2024.

Despite the increase in revenue, the company reported a net loss of $1,886,438 for the second quarter, a 43% improvement from the loss of $3,304,538 in the same quarter of 2024. For the first half of 2025, the net loss was $3,392,305, down from $6,575,497 in the prior year. The improved financial performance is attributed to the Elevai Acquisition, which significantly boosted sales figures. However, operating expenses also rose, with total operating expenses for the second quarter reaching $2,161,262, compared to $1,203,515 in the same period last year.

In terms of strategic developments, Longevity Health completed the Elevai Acquisition on January 16, 2025, acquiring assets related to Elevai's skincare and haircare business. This acquisition is expected to enhance the company's product offerings and market presence. Additionally, the company executed a reverse stock split at a ratio of 1:30 on May 12, 2025, aimed at improving its stock price and compliance with Nasdaq listing requirements. As of June 30, 2025, the company had 1,483,738 shares of common stock outstanding, a significant increase from 696,969 shares at the end of 2024.

Operationally, the company reported a negative working capital of $3,672,761 as of June 30, 2025, and a cash balance of $1,551,199. The company has indicated that it may need to raise additional capital to support its operations, given its ongoing losses and cash flow challenges. The management is exploring options for out-licensing certain research and development programs to enhance liquidity. Furthermore, the company is in the process of completing a merger with True Health Inc., which is expected to provide additional resources and capabilities.

Looking ahead, Longevity Health Holdings faces challenges related to its liquidity and ongoing operational losses. The company has expressed uncertainty about its ability to continue as a going concern without raising additional capital. The management's focus will be on executing the THPlasma Merger and leveraging the Elevai Acquisition to drive future growth. However, the company acknowledges that market conditions and operational challenges could impact its financial stability and growth trajectory.